ClinicalTrials.gg
CompletedNCT00474019Updated Dec 3, 2010

Phase 1 Pharmacokinetics of Intravenous Nexium in Children

A Phase 1 interventional study of esomeprazole in Pharmacokinetics, sponsored by AstraZeneca. Completed at 15 sites in 5 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2010-12-03.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Study summary

The purpose of this research study is to evaluate how much of repeated once daily intravenous (IV, meaning through a vein) doses of esomeprazole gets into the bloodstream of hospitalized children aged 0-17 years old that require acid suppression therapy.

02

Conditions studied

  • Pharmacokinetics

Keywords

  • pediatrics
  • neonates
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • parent/guardian must sign consent form and the child will be asked to sign and Assent Form if he/she is old enough and is able to sign
  • verbal assent will be acceptable if the child is old enough to understand, but unable to write
  • female and/or male hospitalized patients aged 0-17 years old who should be considered for treatment with acid suppressive therapy.

Exclusion criteria

Exclusion Criteria:

  • female patients that are pregnant, or plan to become pregnant during the study period or is breast-feeding a child
  • patients with a history of multiple drug allergies
  • any illness, medical history, abnormal laboratory values, abnormal physical examination findings or abnormal vitals signs that could put the patient at risk when participating in the study
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    1

    Based on age and/or weight dose of esomeprazole IV qd in milligrams 20,40,10,20,10, 1.0 mg/kg, 0,5 mg/kg

    Drug: esomeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic-area under plasma concentration versus time curve within a dosing interval

    Time frame: Day 4 of study

Secondary outcomes

  1. Maximum plasma concentration, total, plasma clearance, steady-state volume of distribution of esomeprazole

    Time frame: Day 4 of study

  2. Safety and tolerability will be assessed by AEs, laboratory values, blood pressure, heart rate, respiratory rate, body temperature, and ECG

    Time frame: Days 1-4 (during treatment), Days 1-28 (post treatment)

  3. Evaluate main metabolites of esomeprazole (sulphone metabolite and 5-hydroxy metabolite) by assessment of max plasma conc, total area under the plasma concentration vs time curve within a dosing interval, clearance scaled by fraction metabolised

    Time frame: Day 4

07

Study locations

15 sites
  • Research Site
    Little Rock, Arkansas, United States
  • Research Site
    Hartford, Connecticut, United States
  • Research Site
    Park Ridge, Illinois, United States
  • Research Site
    Louisville, Kentucky, United States
  • Research Site
    Detroit, Michigan, United States
  • Research Site
    Southfield, Michigan, United States
  • Research Site
    New Brunswick, New Jersey, United States
  • Research Site
    Buffalo, New York, United States
  • Research Site
    Cleveland, Ohio, United States
  • Research Site
    Fort Worth, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    North Adelaide, South Australia, Australia
  • Research Site
    Brussels (jette), Belgium
  • Research Site
    Budapest, Hungary
  • Research Site
    Goteborg, Sweden
08

References and documents

Publications

  • Earp JC, Mehrotra N, Peters KE, Fiorentino RP, Griebel D, Lee SC, Mulberg A, Rohss K, Sandstrom M, Taylor A, Tornoe CW, Wynn EL, Van der Walt JS, Garnett C. Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response. J Pediatr Gastroenterol Nutr. 2017 Sep;65(3):272-277. doi: 10.1097/MPG.0000000000001467. PubMed 27875488 ↗
  • Sandstrom M, Davidson G, Tolia V, Sullivan JE, Langstrom G, Lundborg P, Brown K. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. Clin Ther. 2012 Aug;34(8):1828-38. doi: 10.1016/j.clinthera.2012.06.028. Epub 2012 Jul 24. PubMed 22832034 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2007
First posted
May 16, 2007
Start
Oct 2007
CompletionActual
Oct 2009
Last update
Dec 3, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00474019
Lead sponsor
AstraZeneca
First posted
May 16, 2007
Start date
Oct 2007
Completion
Oct 2009
Last update
Dec 3, 2010

Study contacts

Kurt Brown, MD
study director · AstraZeneca
Per Lundborg, MD
study director · AstraZeneca
Jill McGuinn
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion